Vaccines against human carcinomas: Strategies to improve antitumor immune responses

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Schlom, Jeffrey ^a   Palena, Claudia ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; IPILIMUMAB; LENALIDOMIDE; OBATOCLAX; PLACEBO; TUMOR ANTIGEN; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOMA; CELL ACTIVATION; CELL COMPARTMENTALIZATION; CELL POPULATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG INHIBITION; DRUG TARGETING; ENTEROCOLITIS; HUMAN; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LUNG TUMOR; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NEPHRITIS; NONHUMAN; OVARY CANCER; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; TUMOR GROWTH; BIOLOGICAL MODEL; DRUG EFFECT; IMMUNOLOGY; INNATE IMMUNITY; NEOPLASM;

CANCER VACCINES; HUMANS; IMMUNITY, INNATE; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 77951692791     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/380697     Document Type: Review

References (126)

1. Dunn G. P., Bruce A. T., Ikeda H., Old L. J., Schreiber R. D., Cancer immunoediting: from immunosurveillance to tumor escape Nature Immunology 2002 3 11 991 998 (Pubitemid 35363648)
2. Shankaran V., Ikeda H., Bruce A. T., IFN, and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 2001 410 6832 1107 1111 (Pubitemid 32391043)
3. Girardi M., Glusac E., Filler R. B., The distinct contributions of murine T cell receptor (TCR) + and TCR + T cells to different stages of chemically induced skin cancer Journal of Experimental Medicine 2003 198 5 747 755
4. Smyth M. J., Thia K. Y. T., Street S. E. A., Differential tumor surveillance by natural killer (NK) and NKT cells Journal of Experimental Medicine 2000 191 4 661 668
5. van den Broek M. E., Kagi D., Ossendorp F., Decreased tumor surveillance in perforin-deficient mice Journal of Experimental Medicine 1996 184 5 1781 1790 (Pubitemid 26404469)
6. Pages F., Berger A., Camus M., Effector memory T cells, early metastasis, and survival in colorectal cancer The New England Journal of Medicine 2005 353 25 2654 2666 (Pubitemid 41817714)
7. Galon J., Costes A., Sanchez-Cabo F., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 2006 313 5795 1960 1964 (Pubitemid 44498003)
8. Piersma S. J., Jordanova E. S., van Poelgeest M. I. E., High number of intraepithelial CD 8 + tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer Cancer Research 2007 67 1 354 361
9. Al-Shibli K. I., Donnem T., Al-Saad S., Persson M., Bremnes R. M., Busund L.-T., Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer Clinical Cancer Research 2008 14 16 5220 5227
10. DeNardo D. G., Johansson M., Coussens L. M., Immune cells as mediators of solid tumor metastasis Cancer and Metastasis Reviews 2008 27 1 11 18
11. Yamaguchi T., Sakaguchi S., Regulatory T cells in immune surveillance and treatment of cancer Seminars in Cancer Biology 2006 16 2 115 123 (Pubitemid 43172060)
12. Curiel T. J., Coukos G., Zou L., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nature Medicine 2004 10 9 942 949 (Pubitemid 39273735)
13. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes Trends in Immunology 2002 23 11 549 555 (Pubitemid 35223554)
14. Luo Y., Zhou H., Krueger J., Targeting tumor-associated macrophages as a novel strategy against breast cancer Journal of Clinical Investigation 2006 116 8 2132 2141 (Pubitemid 44162322)
15. DeNardo D. G., Barreto J. B., Andreu P., CD 4 + T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages Cancer Cell 2009 16 2 91 102
16. Ziegler A., Heidenreich R., Braumuller H., EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion Blood 2009 113 15 3494 3502
17. Marincola F. M., Jaffee E. M., Hickljn D. J., Ferrone S., Escape of human solid tumors from t-cell recognition: molecular mechanisms and functional significance Advances in Immunology 2000 74 181 273
18. Dong H., Strome S. E., Salomao D. R., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nature Medicine 2002 8 8 793 800
19. Sica G. L., Choi I.-H., Zhu G., B7-H4, a molecule of the B7 family, negatively regulates T cell immunity Immunity 2003 18 6 849 861 (Pubitemid 36776432)
20. Driessens G., Kline J., Gajewski T. F., Costimulatory and coinhibitory receptors in anti-tumor immunity Immunological Reviews 2009 229 1 126 144
21. Thomas D. A., Massague J., TGF- directly targets cytotoxic T cell functions during tumor evasion of immune surveillance Cancer Cell 2005 8 5 369 380
22. Kurte M., Lopez M., Aguirre A., A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells Journal of Immunology 2004 173 3 1731 1737
23. Terabe M., Matsui S., Noben-Trauth N., NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway Nature Immunology 2000 1 6 515 520
24. Gabrilovich D. I., Chen H. L., Girgis K. R., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells Nature Medicine 1996 2 10 1096 1103
25. Marshall J. L., Hoyer R. J., Toomey M. A., Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses Journal of Clinical Oncology 2000 18 23 3964 3973
26. Boehm A. L., Higgins J., Franzusoff A., Schlom J., Hodge J. W., Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations Cancer Immunology, Immunotherapy 2010 59 3 397 408
27. Cheever M. A., Allison J. P., Ferris A. S., The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research Clinical Cancer Research 2009 15 17 5323 5337
28. van der Bruggen P., Stroobant V., van Pel A., van den Eynde B., T-cell defined tumor antigens. http://www.cancerimmunity.org/peptidedatabase/ Tcellepitopes.htm
29. Abrams S. I., Stanziale S. F., Lunin S. D., Zaremba S., Schlom J., Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD 4 + and CD 8 + T cell responses European Journal of Immunology 1996 26 2 435 443
30. Offringa R., Vierboom M. P. M., van der Burg S. H., Erdile L., Melief C. J. M., p53: a potential target antigen for immunotherapy of cancer Annals of the New York Academy of Sciences 2000 910 223 236
31. Kessler J. H., Bres-Vloemans S. A., van Veelen P. A., BCR-ABL fusion regions as a source of multiple leukemia-specific CD 8 + T-cell epitopes Leukemia 2006 20 10 1738 1750
32. Knutson K. L., Lu H., Stone B., Immunoediting of cancers may lead to epithelial to mesenchymal transition Journal of Immunology 2006 177 3 1526 1533
33. Kmieciak M., Knutson K. L., Dumur C. I., Manjili M. H., HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses European Journal of Immunology 2007 37 3 675 685
34. Jager E., Ringhoffer M., Karbach J., Arand M., Oesch F., Knuth A., Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD 8 + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo International Journal of Cancer 1996 66 4 470 476
35. Hirohashi Y., Torigoe T., Inoda S., The functioning antigens: beyond just as the immunological targets Cancer Science 2009 100 5 798 806
36. Thiery J. P., Sleeman J. P., Complex networks orchestrate epithelial-mesenchymal transitions Nature Reviews Molecular Cell Biology 2006 7 2 131 142
37. Thiery J. P., Epithelial-mesenchymal transitions in tumour progression Nature Reviews Cancer 2002 2 6 442 454
38. Yang J., Mani S. A., Donaher J. L., Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis Cell 2004 117 7 927 939
39. Kwok W. K., Ling M.-T., Lee T.-W., Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target Cancer Research 2005 65 12 5153 5162
40. Kalluri R., Weinberg R. A., The basics of epithelial-mesenchymal transition Journal of Clinical Investigation 2009 119 6 1420 1428
41. Palena C., Polev D. E., Tsang K. Y., The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy Clinical Cancer Research 2007 13 8 2471 2478
42. Fernando R. I., Litzinger M., Trono P., Hamilton D. H., Schlom J., Palena C., The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells Journal of Clinical Investigation 2010 120 2 533 544
43. Kudo-Saito C., Schlom J., Hodge J. W., Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses Clinical Cancer Research 2005 11 6 2416 2426
44. Butterfield L. H., Ribas A., Dissette V. B., Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma Clinical Cancer Research 2003 9 3 998 1008
45. Arlen P. M., Gulley J. L., Parker C., A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer Clinical Cancer Research 2006 12 4 1260 1269
46. Schwartz R. H., A cell culture model for T lymphocyte clonal anergy Science 1990 248 4961 1349 1356
47. Harding F. A., McArthur J. G., Gross J. A., Raulet D. H., Allison J. P., CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones Nature 1992 356 6370 607 609
48. Zang X., Allison J. P., The B7 family and cancer therapy: costimulation and coinhibition Clinical Cancer Research 2007 13 18, part 1 5271 5279
49. Hodge J. W., McLaughlin J. P., Abrams S. I., Shupert W. L., Schlom J., Kantor J. A., Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-Cell responses and antitumor immunity Cancer Research 1995 55 16 3598 3603
50. Hodge J. W., Sabzevari H., Yafal A. G., Gritz L., Lorenz M. G. O., Schlom J., A triad of costimulatory molecules synergize to amplify T-cell activation Cancer Research 1999 59 22 5800 5807
51. Zhu M., Terasawa H., Gulley J., Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells Cancer Research 2001 61 9 3725 3734 (Pubitemid 32694986)
52. Palena C., Zhu M., Schlom J., Tsang K.-Y., Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells Blood 2004 104 1 192 199 (Pubitemid 38879857)
53. Kantoff P. W., Schuetz T. J., Blumenstein B. A., Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology 2010 28 7 1099 1105
54. Gulley J. L., Arlen P. M., Madan R. A., Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer Cancer Immunology, Immunotherapy 2010 59 5 663 674
55. Kass E., Panicali D. L., Mazzara G., Seldom J., Greiner J. W., Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant Cancer Research 2001 61 1 206 214 (Pubitemid 32095719)
56. Kass E., Parker J., Schlom J., Greiner J. W., Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes Cytokine 2000 12 7 960 971 (Pubitemid 30479478)
57. Dranoff G., Jaffee E., Lazenby A., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proceedings of the National Academy of Sciences of the United States of America 1993 90 8 3539 3543 (Pubitemid 23111402)
58. Dranoff G., GM-CSF-secreting melanoma vaccines Oncogene 2003 22 20 3188 3192 (Pubitemid 36713771)
59. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo M. P., Rivoltini L., Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients Annals of Oncology 2007 18 2 226 232 (Pubitemid 46323086)
60. Small E. J., Schellhammer P. F., Higano C. S., Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer Journal of Clinical Oncology 2006 24 19 3089 3094
61. Schellhammer P., Higano C., Berger E., A randomized, double-blind, placebo-controlled multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC) Proceedings of the American Urological Association Annual Meeting April 2009 Chicago, Ill, USA
62. Smith F. O., Downey S. G., Klapper J. A., Treatment of metastatic melanoma using Interleukin-2 alone or in conjunction with vaccines Clinical Cancer Research 2008 14 17 5610 5618
63. Heemskerk B., Liu K., Dudley M. E., Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2 Human Gene Therapy 2008 19 5 496 510 (Pubitemid 351748783)
64. Melchionda F., Fry T. J., Milliron M. J., McKirdy M. A., Tagaya Y., Mackall C. L., Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD 8 + memory cell pool Journal of Clinical Investigation 2005 115 5 1177 1187 (Pubitemid 40629036)
65. Waldmann T. A., The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design Nature Reviews Immunology 2006 6 8 595 601
66. Sato N., Patel H. J., Waldmann T. A., Tagaya Y., The IL-15/IL-15R on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells Proceedings of the National Academy of Sciences of the United States of America 2007 104 2 588 593
67. Cheever M. A., Twelve immunotherapy drugs that could cure cancers Immunological Reviews 2008 222 1 357 368
68. McDermott D. F., Atkins M. B., Immunotherapy of metastatic renal cell carcinoma Cancer Journal 2008 14 5 320 324
69. Petrella T., Quirt I., Verma S., Haynes A. E., Charette M., Bak K., Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review Cancer Treatment Reviews 2007 33 5 484 496 (Pubitemid 47333669)
70. Rosenstein M., Ettinghausen S. E., Rosenberg S. A., Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2 Journal of Immunology 1986 137 5 1735 1742
71. Ahmadzadeh M., Rosenberg S. A., IL-2 administration increases CD 4 + CD25hi Foxp 3 + regulatory T cells in cancer patients Blood 2006 107 6 2409 2414
72. Dudley M. E., Wunderlich J. R., Shelton T. E., Even J., Rosenberg S. A., Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients Journal of Immunotherapy 2003 26 4 332 342
73. Villinger F., Miller R., Mori K., IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques Vaccine 2004 22 25-26 3510 3521
74. Kutzler M. A., Robinson T. M., Chattergoon M. A., Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help Journal of Immunology 2005 175 1 112 123
75. Colombo M. P., Trinchieri G., Interleukin-12 in anti-tumor immunity and immunotherapy Cytokine and Growth Factor Reviews 2002 13 2 155 168
76. Leonard J. P., Sherman M. L., Fisher G. L., Effects of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon- production Blood 1997 90 7 2541 2548
77. Zaharoff D. A., Hoffman B. S., Hooper H. B., Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12 Cancer Research 2009 69 15 6192 6199
78. Chakraborty M., Abrams S. I., Camphausen K., Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy Journal of Immunology 2003 170 12 6338 6347
79. Garnett C. T., Palena C., Chakarborty M., Tsang K.-Y., Schlom J., Hodge J. W., Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes Cancer Research 2004 64 21 7985 7994
80. Reits E. A., Hodge J. W., Herberts C. A., Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy Journal of Experimental Medicine 2006 203 5 1259 1271
81. Chakraborty M., Abrams S. I., Coleman C. N., Camphausen K., Schlom J., Hodge J. W., External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing Cancer Research 2004 64 12 4328 4337
82. Gulley J. L., Arlen P. M., Bastian A., Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer Clinical Cancer Research 2005 11 9 3353 3362
83. Lake R. A., van der Most R. G., A better way for a cancer cell to die The New England Journal of Medicine 2006 354 23 2503 2504
84. Tesniere A., Schlemmer F., Boige V., Immunogenic death of colon cancer cells treated with oxaliplatin Oncogene 2010 29 4 482 491
85. Bergmann-Leitner E. S., Abrams S. I., Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD 8 + cytotoxic T lymphocytes Cancer Immunology, Immunotherapy 2001 50 9 445 455
86. Wu X. X., Zeng Y., Jin X. H., Kakehi Y., Enhanced susceptibility of adriamycin-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes and tumor infiltrating lymphocytes Oncology Reports 2007 18 2 353 359
87. Chan O. T. M., Yang L.-X., The immunological effects of taxanes Cancer Immunology, Immunotherapy 2000 49 4-5 181 185
88. Garnett C. T., Schlom J., Hodge J. W., Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement Clinical Cancer Research 2008 14 11 3536 3544
89. Machiels J.-P. H., Reilly R. T., Emens L. A., Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Research 2001 61 9 3689 3697
90. Galustian C., Labarthe M.-C., Bartlett J. B., Dalgleish A. G., Thalidomide-derived immunomodulatory drugs as therapeutic agents Expert Opinion on Biological Therapy 2004 4 12 1963 1970
91. Galustian C., Meyer B., Labarthe M.-C., The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells Cancer Immunology, Immunotherapy 2009 58 7 1033 1045
92. Farsaci B., Sabzevari H., Di Bari M. G., Takai S., Schlom J., Hodge J. W., Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. International Journal of Cancer, 2010 Jan 20. [Epub ahead of print]
93. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proceedings of the National Academy of Sciences of the United States of America 2002 99 19 12293 12297
94. Hirano F., Kaneko K., Tamura H., Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Research 2005 65 3 1089 1096
95. Prasad D. V. R., Richards S., Mai X. M., Dong C., B7S1, a novel B7 family member that negatively regulates T cell activation Immunity 2003 18 6 863 873
96. Tringler B., Zhuo S., Pilkington G., B7-H4 is highly expressed in ductal and lobular breast cancer Clinical Cancer Research 2005 11 5 1842 1848
97. Tringler B., Liu W., Corral L., B7-H4 overexpression in ovarian tumors Gynecologic Oncology 2006 100 1 44 52
98. Sun Y., Wang Y., Zhao J., B7-H3 and B7-H4 expression in non-small-cell lung cancer Lung Cancer 2006 53 2 143 151
99. Krambeck A. E., Thompson R. H., Dong H., B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival Proceedings of the National Academy of Sciences of the United States of America 2006 103 27 10391 10396
100. Egen J. G., Allison J. P., Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength Immunity 2002 16 1 23 35
101. Egen J. G., Kuhns M. S., Allison J. P., CTLA-4: new insights into its biological function and use in tumor immunotherapy Nature Immunology 2002 3 7 611 618
102. Hodge J. W., Chakraborty M., Kudo-Saito C., Garnett C. T., Schlom J., Multiple costimulatory modalities enhance CTL avidity Journal of Immunology 2005 174 10 5994 6004
103. Sarnaik A. A., Weber J. S., Recent advances using anti-CTLA-4 for the treatment of melanoma Cancer Journal 2009 15 3 169 173
104. Beck K. E., Blansfield J. A., Tran K. Q., Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 Journal of Clinical Oncology 2006 24 15 2283 2289
105. Blansfield J. A., Beck K. E., Tran K., Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer Journal of Immunotherapy 2005 28 6 593 598
106. Gavin M., Rudensky A., Control of immune homeostasis by naturally arising regulatory CD 4 + T cells Current Opinion in Immunology 2003 15 6 690 696
107. Sakaguchi S., Naturally arising Foxp3-expressing CD 25 + CD 4 + regulatory T cells in immunological tolerance to self and non-self Nature Immunology 2005 6 4 345 352
108. Woo E. Y., Chu C. S., Goletz T. J., Regulatory CD 4 + CD 25 + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Research 2001 61 12 4766 4772
109. Wolf A. M., Wolf D., Steurer M., Gastl G., Gunsilius E., Grubeck-Loebenstein B., Increase of regulatory T cells in the peripheral blood of cancer patients Clinical Cancer Research 2003 9 2 606 612
110. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor ) monoclonal antibody Cancer Research 1999 59 13 3128 3133
111. Shimizu J., Yamazaki S., Sakaguchi S., Induction of tumor immunity by removing CD 25 + CD 4 + T cells: a common basis between tumor immunity and autoimmunity Journal of Immunology 1999 163 10 5211 5218
112. Kudo-Saito C., Schlom J., Camphausen K., Coleman C. N., Hodge J. W., The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors Clinical Cancer Research 2005 11 12 4533 4544
113. Litzinger M. T., Fernando R., Curiel T. J., Grosenbach D. W., Schlom J., Palena C., IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity Blood 2007 110 9 3192 3201
114. Barnett B., Kryczek I., Cheng P., Zou W., Curiel T. J., Regulatory T cells in ovarian cancer: biology and therapeutic potential American Journal of Reproductive Immunology 2005 54 6 369 377
115. Mahnke K., Schonfeld K., Fondel S., Depletion of CD 4 + CD 25 + human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro International Journal of Cancer 2007 120 12 2723 2733
116. Morse M. A., Hobeika A. C., Osada T., Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines Blood 2008 112 3 610 618
117. Dannull J., Su Z., Rizzieri D., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells Journal of Clinical Investigation 2005 115 12 3623 3633
118. Blobe G. C., Schiemann W. P., Lodish H. F., Role of transforming growth factor in human disease The New England Journal of Medicine 2000 342 18 1350 1358
119. Teicher B. A., Malignant cells, directors of the malignant process: role of transforming growth factor-beta Cancer and Metastasis Reviews 2001 20 1-2 133 143
120. Wrzesinski S. H., Wan Y. Y., Flavell R. A., Transforming growth factor- and the immune response: implications for anticancer therapy Clinical Cancer Research 2007 13 18, part 1 5262 5270
121. di Bari M. G., Lutsiak M. E., Takai S., TGF-beta modulates the functionality of tumor-infiltrating CD 8 + T cells through effects on TCR signaling and Spred1 expression Cancer Immunology, Immunotherapy 2009 58 11 1809 1818
122. Terabe M., Ambrosino E., Takaku S., Synergistic enhancement of CD 8 + T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor- monoclonal antibody Clinical Cancer Research 2009 15 21 6560 6569
123. Folkman J., Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Medicine 1995 1 1 27 31
124. Kim K. J., Li B., Winer J., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 1993 362 6423 841 844
125. Allavena P., Sica A., Garlanda C., Mantovani A., The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance Immunological Reviews 2008 222 1 155 161
126. Gabrilovich D. I., Ishida T., Nadaf S., Ohm J. E., Carbone D. P., Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function Clinical Cancer Research 1999 5 10 2963 2970